Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

This paper reviews the role of beta-blockers in the prevention of cardiovascular morbidity and mortality in patients with diabetes mellitus. There is good evidence from randomized controlled trials that beta-blockers, in particular the lipophilic agents, substantially reduce cardiovascular mortality and morbidity. However, hitherto beta-blockers have been underused in diabetic patients, perhaps because of perceived risks of beta-blocker therapy. Reappraisal of the evidence suggests that the traditional reluctance to use beta-blockers in this group is based on fears of adverse effects that are largely unfounded.

Original publication

DOI

10.1046/j.1365-2710.2002.00419.x

Type

Journal article

Journal

Journal of clinical pharmacy and therapeutics

Publication Date

08/2002

Volume

27

Pages

233 - 242

Addresses

Division of Medical Sciences, University of Birmingham, Birmingham, UK.

Keywords

Humans, Death, Sudden, Cardiac, Coronary Disease, Diabetes Complications, Adrenergic beta-Antagonists, Prospective Studies, Physician's Practice Patterns